Evidence map›Paper›PMID 34466632›Full record

ArticleRegenerative therapy2021

Safety and efficacy of bone marrow derived-mesenchymal stem cells transplantation in patients with amyotrophic lateral sclerosis.

Jalil Tavakol-Afshari, Amir Reza Boroumand, Najmeh Kaffash Farkhad, Amir Adhami Moghadam, Sajad Sahab-Negah, Ali Gorji

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Regenerative therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jalil Tavakol-AfshariImmunology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Amir Reza BoroumandNeuroscience Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Najmeh Kaffash FarkhadImmunology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Amir Adhami MoghadamDepartment of Internal Medicine and Critical Care, Islamic Azad University, Mashhad, Iran.
Sajad Sahab-NegahNeuroscience Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Ali GorjiNeuroscience Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stem cell-based treatments have emerged as potentially effective approaches to delay the progression of amyotrophic lateral sclerosis (ALS). This study was designed as a single-center, prospective, and open-label study without a placebo control group to assess the safety and efficacy of concurrent intrathecal (IT) and intravenous (IV) administration of autologous bone marrow-derived mesenchymal stem cells (BM-MSCs) in patients with ALS. Autologous BM-MSCs were isolated and expanded under standard conditions. Fifteen patients were neurologically examined before BM-MSCs transplantation (1 × 10

Indexed as

Amyotrophic lateral sclerosisClinical trialStem cell therapy

Identifiers

PMID34466632
PMCPMC8377537

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.